This company listing is no longer active
Wockhardt Bio Past Earnings Performance
Past criteria checks 0/6
Wockhardt Bio's earnings have been declining at an average annual rate of -108%, while the Biotechs industry saw earnings growing at 11% annually. Revenues have been growing at an average rate of 12.1% per year.
Key information
-108.0%
Earnings growth rate
-108.0%
EPS growth rate
| Biotechs Industry Growth | 18.9% |
| Revenue growth rate | 12.1% |
| Return on equity | -1.1% |
| Net Margin | -1.0% |
| Last Earnings Update | 31 Mar 2022 |
Recent past performance updates
Revenue & Expenses BreakdownBeta
How Wockhardt Bio makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 22 | 297 | -3 | 69 | 0 |
| 31 Mar 21 | 265 | 37 | 67 | 0 |
| 31 Mar 20 | 315 | 25 | 64 | 0 |
| 31 Mar 19 | 337 | -23 | 70 | 0 |
| 31 Mar 18 | 336 | -60 | 66 | 0 |
| 31 Mar 17 | 331 | -45 | 74 | 0 |
| 31 Dec 16 | 349 | -22 | 72 | 0 |
| 30 Sep 16 | 367 | 2 | 70 | 0 |
| 30 Jun 16 | 393 | 16 | 71 | 0 |
| 31 Mar 16 | 418 | 27 | 72 | 0 |
| 31 Dec 15 | 422 | 34 | 68 | 0 |
| 30 Sep 15 | 426 | 41 | 63 | 0 |
| 30 Jun 15 | 416 | 34 | 57 | 0 |
| 31 Mar 15 | 406 | 27 | 50 | 0 |
| 31 Dec 14 | 452 | 28 | 51 | 0 |
| 30 Sep 14 | 478 | 24 | 50 | 0 |
| 30 Jun 14 | 534 | 59 | 50 | 0 |
| 31 Mar 14 | 590 | 95 | 49 | 0 |
| 31 Dec 13 | 661 | 145 | 50 | 0 |
| 30 Sep 13 | 783 | 226 | 53 | 0 |
| 30 Jun 13 | 790 | 284 | 52 | 0 |
| 31 Mar 13 | 798 | 348 | 51 | 0 |
Quality Earnings: WBIO is currently unprofitable.
Growing Profit Margin: WBIO is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if WBIO's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare WBIO's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: WBIO is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-12%).
Return on Equity
High ROE: WBIO has a negative Return on Equity (-1.06%), as it is currently unprofitable.